Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) have announced an amendment to their collaboration agreement, along with a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share. This equity…
In Q4 2023, Sanofi experienced a robust sales growth of 9.3% at Constant Exchange Rates (CER) and an 8.2% increase in business EPS. Notable achievements include Specialty Care’s 13.7% growth fueled by the success of Dupixent and ALTUVIIIO launches, which…
Roche (SIX: RO, ROG; OTCQX: RHHBY) has disclosed compelling 72-week data derived from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab) in the treatment of macular edema stemming from branch and central retinal vein occlusion (BRVO and…
Novo Nordisk’s sales increased by 31% in Danish kroner and by 36% at constant exchange rates to DKK 232.3 billion in 2023 PROFIT AND LOSS 2023 2022 Growthas reported Growthat CER* DKK million Net sales 232,261…
ObjectiveHealth, a leading integrated specialty research network and technology company, announced today that it has secured a strategic growth investment from Vitruvian Partners, a leading global growth-focused investment firm. ObjectiveHealth is an innovator in clinical research, seamlessly integrating clinical trials…
Merck, a leading science and technology company, has signed a 10-year green power purchase agreement (PPA) with China Resources Power Holdings Co., Ltd. This is Merck’s first long-term renewable energy procurement in China, with an expected consumption of 300 gigawatt…
Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization approval of Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed and refractory multiple…
The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic esophagitis (EoE). Dupixent is now the first and only medicine approved in…
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, “Astellas”) today announced that on January 26 the European Medicines Agency (EMA) validated for review a Type II variation application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) as…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 AMBASSADOR (A031501)/KEYNOTE-123 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, for the adjuvant treatment of high-risk patients with localized muscle-invasive urothelial carcinoma…
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in this year’s Regeneron Science Talent Search, the nation’s oldest and most prestigious science and math competition for high school seniors. The competition, now in its 83rd year, has consistently…
Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Mirati Therapeutics, Inc.® (“Mirati”). With the completion of the acquisition, Mirati shares have ceased trading on the NASDAQ Global Select Market and Mirati is now a…
